fahrbot-bot shares a report from The Guardian: Scientists have discovered an entirely new class of antibiotic that appears to kill one of three bacteria considered to pose the greatest threat to human health because of their extensive drug-resistance. Zosurabalpin defeated highly drug-resistant strains of Carbapenem-resistant Acinetobacter baumannii (Crab) in mouse models of pneumonia and sepsis, and was being tested in human trials. Crab is classified as a priority 1 critical pathogen by the World Health Organization, alongside two other drug-resistant forms of bacteria -- Pseudomonas aeruginosa and Enterobacteriaceae.

Antibiotic-resistant infections pose an urgent threat to human health -- particularly those caused by a large group of bacteria known as Gram-negative bacteria, which are protected by an outer shell containing a substance called lipopolysaccharide (LPS). "LPS allows bacteria to live in harsh environments, and it also allows them to evade attack by our immune system," said Dr Michael Lobritz, the global head of infectious diseases at Roche Pharma Research and Early Development in Basel Switzerland, which developed the new drug. No new antibiotic for Gram-negative bacteria have been approved in more than 50 years.

Roche had previously identified Zosurabalpin as capable of blocking the growth of A baumannii but it was not clear how it worked, or if it would be effective in animals with Crab-related infections. Through a series of experiments published in Nature, Prof Daniel Kahne at Harvard University in Cambridge, US, and colleagues showed that the drug prevented LPS from being transported to the outer membrane of the bacterium, killing it. They also found that Zosurabalpin considerably reduced levels of bacteria in mice with Crab-induced pneumonia and prevented the death of those with Crab-related sepsis. While [Lobritz] stressed that this molecule alone would not solve the public health threat of antimicrobial resistant infections, the discovery could lay the foundations for future efforts to drug the same transport system in other bacteria.

An anonymous reader quotes a report from Technology Networks: At about the size of a pinkie nail, the jellyfish species Cladonema can regenerate an amputated tentacle in two to three days -- but how? Regenerating functional tissue across species, including salamanders and insects, relies on the ability to form a blastema, a clump of undifferentiated cells that can repair damage and grow into the missing appendage. Jellyfish, along with other cnidarians such as corals and sea anemones, exhibit high regeneration abilities, but how they form the critical blastema has remained a mystery until now.

A research team based in Japan has revealed that stem-like proliferative cells -- which are actively growing and dividing but not yet differentiating into specific cell types -- appear at the site of injury and help form the blastema. "Importantly, these stem-like proliferative cells in blastema are different from the resident stem cells localized in the tentacle," said corresponding author Yuichiro Nakajima, lecturer in the Graduate School of Pharmaceutical Sciences at the University of Tokyo. "Repair-specific proliferative cells mainly contribute to the epithelium -- the thin outer layer -- of the newly formed tentacle."

The resident stem cells that exist in and near the tentacle are responsible for generating all cellular lineages during homeostasis and regeneration, meaning they maintain and repair whatever cells are needed during the jellyfish's lifetime, according to Nakajima. Repair-specific proliferative cells only appear at the time of injury. "Together, resident stem cells and repair-specific proliferative cells allow rapid regeneration of the functional tentacle within a few days," Nakajima said, noting that jellyfish use their tentacles to hunt and feed. [...] The cellular origins of the repair-specific proliferative cells observed in the blastema remain unclear, though, and the researchers say the currently available tools to investigate the origins are too limited to elucidate the source of those cells or to identify other, different stem-like cells. "It would be essential to introduce genetic tools that allow the tracing of specific cell lineages and the manipulation in Cladonema," Nakajima said. "Ultimately, understanding blastema formation mechanisms in regenerative animals, including jellyfish, may help us identify cellular and molecular components that improve our own regenerative abilities."

The findings were published in the journal PLOS Biology.

Longtime Slashdot reader fahrbot-bot shares a report from ScienceAlert: According to a new study [published in Nature Human Behavior], the human brain has two separate ways of processing numbers of things: one system for quantities of four or fewer, and another system for five and up. Presented with four or fewer objects, humans can usually identify the sum at first glance, without counting. And we're almost always right. This ability is known as "subitizing," a term coined by psychologists last century, and it's different from both counting and estimating. It refers to an uncanny sense of immediately knowing how many things you're looking at, with no tallying or guessing required.

While we can easily subitize quantities up to four, however, the ability disappears when we're looking at five or more things. If asked to instantly quantify a group of seven apples, for example, we tend to hesitate and estimate, taking slightly longer to respond and still providing less precise answers. Since our subitizing skills vanish so abruptly for quantities larger than four, some researchers have suspected our brains use two distinct processing methods, specialized for either small or large quantities. "However, this idea has been disputed up to now," says co-author Florian Mormann, a cognitive neurophysiologist from the Department of Epileptology at the University Hospital Bonn. "It could also be that our brain always makes an estimate but the error rates for smaller numbers of things are so low that they simply go unnoticed."

Previous research involving some of the new study's authors showed that human brains have neurons responsible for each number, with certain nerve cells firing selectively in response to certain quantities. Some neurons fire mainly when a person sees two of something, they found, while others show a similar affinity for their own number of visual elements. Yet many of these neurons also fire in response to slightly smaller or larger numbers, the researchers note, with a weaker reaction for quantities further removed from their numerical focus. "A brain cell for a number of 'seven' elements thus also fires for six and eight elements but more weakly," says neurobiologist Andreas Nieder from the University of Tubingen. "The same cell is still activated but even less so for five or nine elements."

This kind of "numerical distance effect" also occurs in monkeys, as Nieder has shown in previous research. Among humans, however, it typically happens only when we see five or more things, hinting at some undiscovered difference in the way we identify smaller numbers. "There seems to be an additional mechanism for numbers of around less than five elements that makes these neurons more precise," Nieder says. Neurons responsible for lower numbers are able to inhibit other neurons responsible for adjacent numbers, the study's authors report, thus limiting any mixed signals about the quantity in question. When a trio-specializing neuron fires, for example, it also inhibits the neurons that typically fire in response to groups of two or four things. Neurons for the number five and beyond apparently lack this mechanism.

India launched its first satellite on Monday to study black holes as it seeks to deepen its space exploration efforts ahead of an ambitious crewed mission next year. From a report: The spacecraft, named X-ray Polarimeter Satellite, was propelled into an orbit of 350 kilometers from an island near India's main spaceport of Sriharikota, off the southern state of Andhra Pradesh, according to S. Somanath, chairman of the Indian Space Research Organisation. The satellite, weighing about 470 kilograms, will carry out research on X-rays emanating from around 50 celestial objects with the help of two payloads built by ISRO and a Bengaluru-based research institute.

NASA launched a similar mission, the Imaging X-ray Polarimetry Explorer, in 2021 to answer questions such as why black holes spin and build on the findings of its flagship telescope Chandra X-ray Observatory that blasted off more than two decades ago. China's National Space Administration launched the country's first X-ray space telescope to observe black holes, pulsars and gamma-ray bursts in 2017.

"This year has been a major turning point in American health care," reports USA Today, "and patients can anticipate several major developments in the new year," including the beginning of a CRISPR "revolution" and "a new reckoning with drug prices that could change the landscape of the U.S. health care system for decades to come." Health care officials expect 2024 to bring a wave of innovation and change in medicine, treatment and public health... Many think 2024 could be the year more people have the tools to follow through on New Year's resolutions about weight loss. If they can afford them and manage to stick with them, people can turn to a new generation of remarkably effective weight-loss drugs, also called GLP-1s, which offer the potential for substantial weight loss...

In 2023, mental health issues became among the nation's most deadly, costly and pervasive health crises... The dearth of remedies has also paved the way for an unsuspecting class of drugs: psychedelics. MDMA, a party drug commonly known as "ecstasy," could win approval for legal distribution in 2024, as a treatment for post-traumatic stress disorder. Another psychedelic, a ketamine derivative eskatemine, sold as Spravato, was approved in 2019 to treat depression, but it is being treated like a conventional therapy that must be dosed regularly, not like a psychedelic that provides a long-lasting learning experience, said Matthew Johnson, an expert in psychedelics at Johns Hopkins University. MDMA (midomafetamine capsules) would be different, as the first true psychedelic to win FDA approval.

In a late-stage trial of patients with moderate or severe post-traumatic stress disorder, close to 90% showed clinically significant improvements four months after three treatments with MDMA and more than 70% no longer met the criteria for having the disorder, which represented "really impressive results," according to Matthew Johnson, an expert in psychedelics at Johns Hopkins University in Maryland. Psilocybin, known colloquially as "magic mushrooms," is also working its way through the federal approval process, but it likely won't come up before officials for another year, Johnson said. Psychedelics are something to keep an eye on in the future, as they're being used to treat an array of mental health issues: eskatimine for depression, MDMA for PTSD and psilocybin for addiction. Johnson said his research suggests that psychedelics will probably have a generalizable benefit across many mental health challenges in the years to come.
2024 will also be the first year America's drug-makers face new limits on how much they can increase prices for drugs covered by the federal health insurance program Medicare.

"Navajo Nation President Buu Nygren has asked NASA to delay a scheduled launch to the Moon that could include cremated remains," reports Arizona Public Radio station KNAU: Nygren says he recently learned of the January 8 launch of the Vulcan Centaur carrying the Peregrine Mission One. The lander will carry some payloads from a company known to provide memorial services by shipping human cremated remains to the Moon. Nygren wants the launch delayed and the tribe consulted immediately. He noted the Moon is sacred to numerous Indigenous cultures and that depositing human remains on it is "tantamount to desecration."

NASA previously came under fire after the ashes of former geologist and planetary scientist Eugene Shoemaker were sent to the Moon in 1998. Then-Navajo Nation President Albert Hale said the action was a gross insensitivity to the beliefs of many Native Americans. NASA later apologized and promised to consult with tribes before authorizing any similar missions in the future.

What would happen if we built a concert venue in near-Earth orbit? A science policy journalist explores the question in the Washington Post: Forget U2 in the Las Vegas Sphere. Take me to a real concert in the round, where I can float 360 degrees around the stage, watching a guitarist shred from the perspective of a fly and inventing dance moves that Earth's gravity would forbid.

Before you dismiss this as a hallucination, consider that we're on the cusp of a new era of space travel. Engineer and space architect Ariel Ekblaw, founder of MIT's Space Exploration Initiative, says that within a decade, a trip off the planet could become as accessible as a first-class airline ticket — and that, in 15 or 20 years, we can expect space hotels in near-Earth orbit. She's betting on it, having founded a nonprofit to design spherical, modular habitats that can assemble themselves in space so as to be lightweight and compact at launch, much like the James Webb Space Telescope that NASA vaulted into deep space two years ago.

"The first era of space travel was about survival," she told me as I recently toured her lab. "We're transitioning now to build spaces that are friendlier and more welcoming so that people can thrive in space as opposed to just survive." There's no reason, Ekblaw said, that a concert hall can't be one of those structures.
The article ultimately calls this "an impulse for space travel I can get behind: curiosity about who we are and what more we can create when we reach beyond Earth. This is the realm of not just scientists and engineers but of all kinds of dreamers. It's a rendition of space exploration that can engage anyone to imagine what's possible."

As the year comes to a close, "one constant, reliable source of awe and beauty is the sky over our head..." writes astronomer Phil Plait in Scientific America

"And every year we see new things, or old things in new ways, and I've been set the wonderful task of selecting my favorites and relaying them and their import to you." End-of-year lists, especially those displaying astronomical imagery, tend to be splashy and colorful. That's understandable, but what they sometimes miss are the more subtle photographs, those that hide momentous discoveries in minor visual details or offer fresh perspectives on familiar objects. They may not leap off the page, but they still have an impact. That's what I've kept in mind while sorting through this year's celestial treasure trove. This gallery is by no means complete, but it shows what I think are some of the most interesting astronomical portraits to have emerged in 2023.

No gallery such as this would be complete without something from the James Webb Space Telescope (JWST), our newest infrared eye on the sky. This monster observatory has already brought so many small revolutions to astronomy that picking one from the past year is no small task. Should it be a baby star throwing an immense tantrum or a massive old star shedding material at colossal rates before it inevitably explodes as a supernova? Or should it be a map of a mind-stomping 100,000 galaxies?

Well, how about something very, very different — such as the skeletal structure of a nearby galaxy's intricate web of dust [also displayed at the top of Scientiic American's article]...? [I]t has a beautiful spiral structure and shows the effects of a smaller galaxy colliding with it. In the phenomenally sharp and decidedly eerie false-color view from JWST's Mid-Infrared Instrument, we see countless clouds of cosmic dust in a skeletonlike pattern. Each of these clouds is made up of small grains of rocky and sooty carbon-based molecules expelled by dying stars...

Astronomers captured this image to better understand how stars are born in stellar nurseries and how they evolve over time.

"[F]or years it was written off," writes CNN. " 'The economics were just way out,' said Martin Soltau, CEO of the UK-based company Space Solar.

"That may now be changing as the cost of launching satellites falls sharply, solar and robotics technology advances swiftly, and the need for abundant clean energy to replace planet-heating fossil fuels becomes more urgent." There's a "nexus of different technologies coming together right now just when we need it," said Craig Underwood, emeritus professor of spacecraft engineering at the University of Surrey in the U.K. The problem is, these technologies would need to be deployed at a scale unlike anything ever done before... "The big stumbling block has been simply the sheer cost of putting a power station into orbit." Over the last decade, that has begun to change as companies such as SpaceX and Blue Origin started developing reusable rockets. Today's launch costs at around $1,500 per kilogram are about 30 times less than in the Space Shuttle era of the early 1980s.

And while launching thousands of tons of material into space sounds like it would have a huge carbon footprint, space solar would likely have a footprint at least comparable to terrestrial solar per unit of energy, if not a smaller, because of its increased efficiency as sunlight is available nearly constantly, said Mamatha Maheshwarappa, payload systems lead at UK Space Agency. Some experts go further. Underwood said the carbon footprint of space-based solar would be around half that of a terrestrial solar farm producing the same power, even with the rocket launch...

There is still a huge gulf between concept and commercialization. We know how to build a satellite, and we know how to build a solar array, Maheshwarappa said. "What we don't know is how to build something this big in space..." Scientists also need to figure out how to use AI and robotics to construct and maintain these structures in space. "The enabling technologies are still in a very low technology readiness," Maheshwarappa said. Then there's regulating this new energy system, to ensure the satellites are built sustainably, there's no debris risk, and they have an end-of-life plan, as well as to determine where rectenna sites should be located. Public buy-in could be another huge obstacle, Maheshwarappa said. There can be an instinctive fear when it comes to beaming power from space.

But such fears are unfounded, according to some experts. The energy density at the center of the rectenna would be about a quarter of the midday sun. "It is no different than standing in front of a heat lamp," Hajimiri said.
The article argues that governments and companies around the world "believe there is huge promise in space-based solar to help meet burgeoning demand for abundant, clean energy and tackle the climate crisis." And they cite several specific examples:

• In 2020 the U.S. Naval Research Lab launched a module on an orbital test vehicle, to test solar hardware in space conditions.

• This year Caltech electrical engineering professor led a team that successfully launched a 30-centimeter prototype equipped with transmitters — and successfully beamed detectable energy down to earth.

• In June the U.K. government announced over $5 million in funding to universities and tech companies "to drive forward innovation" in the space-based solar sector.

• The U.S. Air Force Research Lab plans to launch a small demonstrator in 2025.

• Europe's its Solaris program aims to prove "the technical and political viability of space-based solar, in preparation for a possible decision in 2025 to launch a full development program."

• One Chinese spacecraft designer and manufacturer hopes to send a solar satellite into low orbit in 2028 and high orbit by 2030, according to a 2022 South China Morning News report.

An anonymous reader quotes a report from New Atlas: Researchers have developed a new, lightweight foam made from carbon nanotubes that, when used as a helmet liner, absorbed the kinetic energy caused by an impact almost 30 times better than liners currently used in US military helmets. The foam could prevent or significantly reduce the likelihood of concussion in military personnel and sportspeople. Among sportspeople and military vets, traumatic brain injury (TBI) is one of the major causes of permanent disability and death. Injury statistics show that the majority of TBIs, of which concussion is a subtype, are associated with oblique impacts, which subject the brain to a combination of linear and rotational kinetic energy forces and cause shearing of the delicate brain tissue.

To improve their effectiveness, helmets worn by military personnel and sportspeople must employ a liner material that limits both. This is where researchers from the University of Wisconsin-Madison come in. Determined to prevent -- or lessen the effect of -- TBIs caused by knocks to the body and head, they've developed a new lightweight foam material for use as a helmet liner. For the current study, Thevamaran built upon his previous research into vertically aligned carbon nanotube (VACNT) foams -- carefully arranged layers of carbon cylinders one atom thick -- and their exceptional shock-absorbing capabilities. Current helmets attempt to reduce rotational motion by allowing a sliding motion between the wearer's head and the helmet during impact. However, the researchers say this movement doesn't dissipate energy in shear and can jam when severely compressed following a blow. Instead, their novel foam doesn't rely on sliding layers.

VACNT foam sidesteps this shortcoming via its unique deformation mechanism. Under compression, the VACNTs undergo collective sequentially progressive buckling, from increased compliance at low shear strain levels to a stiffening response at high strain levels. The formed compression buckles unfold completely, enabling the VACNT foam to accommodate large shear strains before returning to a near initial state when the load is removed. The researchers found that at 25% precompression, the foam exhibited almost 30 times higher energy dissipation in shear -- up to 50% shear strain -- than polyurethane-based elastomeric foams of similar density. The study has been published in the journal Experimental Mechanics.

SpaceX on Thursday launched two rockets into orbit, only three hours apart, bringing its total number of launches to 98 in 2023. Space.com reports: The first SpaceX mission to take to the skies Thursday (Dec. 28) was a Falcon Heavy rocket carrying the U.S. military's secretive X-37B space plane, designed mission USSF-52. That blasted off from NASA's Kennedy Space Center in Florida at 8:07 p.m. EST (0107 GMT on Dec. 29). This marked the second Falcon Heavy flight of 2023. Second up on the launch docket for Thursday, hours later, was a Falcon 9 liftoff carrying 23 SpaceX Starlink units to low Earth orbit from nearby Cape Canaveral Space Force Station. This launch took place at 11:01 p.m. EST (0401 GMT on Dec. 29). This was SpaceX's 98th and final launch of 2023, and the 96th flight for a Falcon 9 rocket this year.

SpaceX's 97th launch overall for this year marked the seventh flight for X-37B, but the first time the space plane hitched a lift atop a Falcon Heavy rocket. The X-37B/Falcon Heavy launch had been scrubbed several times previously due to bad weather and an issue with ground equipment. The launch of 23 Starlink broadband satellites from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station in Florida that capped off 2023 was also the 96th launch of a Falcon 9 rocket during this year. SpaceX's next launch is targeted for Jan. 2, 2024 and will see a further 21 Starlink satellites lift to orbit to join the over 5,500 internet supplying units currently orbiting Earth.

In 2021, Philips pulled its popular sleep apnea machines and ventilators off the shelves after discovering that an industrial foam built into the devices to reduce noise could release toxic particles and fumes into the masks worn by patients. "But as Philips publicly pledged to send out replacements, supervisors inside the company's headquarters near Pittsburgh were quietly racing to manage a new crisis that threatened the massive recall and posed risks to patients all over again," reports ProPublica. "Tests by independent laboratories retained by Philips had found that a different foam used by the company -- material fitted inside the millions of replacement machines -- was also emitting dangerous chemicals, including formaldehyde, a known carcinogen."

"Though Philips has said the machines are safe, ProPublica and the Pittsburgh Post-Gazette obtained test results and other internal records that reveal for the first time how scientists working for the company grew increasingly alarmed and how infighting broke out as the new threat reached the highest levels of the Pittsburgh operation. The findings also underscore an unchecked pattern of corporate secrecy that began long before Philips decided to use the new foam." From the report: The company had previously failed to disclose complaints about the original foam in its profitable breathing machines, a polyester-based polyurethane material that was found to degrade in heat and humidity. Former patients and others have described hundreds of deaths and thousands of cases of cancer in government reports. After the introduction of the new foam in 2021, this one made of silicone, the company again held back details about the problem from the public even as it sent out replacement machines with the new material to customers around the world.

One of the devices was the DreamStation 2, a newly released continuous positive airway pressure, or CPAP, machine promoted as one of the company's primary replacements. Federal regulators were alerted to the concern more than two years ago but said in a news release at the time that the company was carrying out additional tests on the foam and that patients should keep using their replacements until more details were available. The Food and Drug Administration has not provided new information on the test results since then, and it is still unclear whether the material is safe. That leaves millions of people in the United States alone caught in the middle, including those with sleep apnea, which causes breathing to stop and start through the night and can lead to heart attacks, strokes and sudden death.

The new foam isn't the only problem: An internal investigation at Philips launched in the months after the recall found that water was condensing in the circuitry of the DreamStation 2, creating a new series of safety risks. "Loss of therapy, thermal events, and shock hazards," the investigation concluded. The FDA issued an alert about overheating last month, warning that the devices could produce "fire, smoke, burns, and other signs of overheating" and advising patients to keep the machines away from carpet, fabric and "other flammable materials." Philips has said that customers could continue using the devices if they followed safety instructions. ...

An anonymous reader quotes a report from Bloomberg, written by Naomi Kresge: In the early days of the Covid-19 pandemic, hundreds of scientists from all over the world banded together in an open-source effort to develop an antiviral that would be available for all. They could never have anticipated the many roadblocks they would face along the way, including the Russian invasion of Ukraine, which made refugees out of a group of Kyiv chemists who were doing important work for the project. The group, which called itself Covid Moonshot, hasn't given up on its effort to introduce a more affordable, patent-free treatment for the virus. Their open-source Covid antiviral, now funded by Wellcome, is on track to be ready for human testing within the next year and a half, according to Annette von Delft, a University of Oxford scientist and one of the Moonshot group's leaders. More early discovery work on a range of potential inhibitors for other viruses is also still going on and being funded by a US government grant.

"It's a bit like a proof of concept," von Delft says, for bringing a patent-free experimental drug into the clinic, a model that could be repurposed as a tool to fight neglected tropical diseases or antimicrobial resistance, or prepare for future pandemics. "Can we come up with a strategic model that can help those kinds of compounds with less of a business case along?" Of course, there was definitely a business case for a Covid antiviral, and some of the biggest drugmakers rushed to develop them. In 2022, Pfizer Inc.'s Paxlovid was one of the world's best-selling medicines with $18.9 billion in revenue. Demand has since cratered for the pill, which needs to be given shortly after infection and can't be taken alongside a number of other commonly prescribed medicines. Analysts expect the Paxlovid revenue to plunge just shy of $1 billion this year.

However, there is still a need for a better Covid antiviral, particularly in countries where access to the Pfizer pill is limited, according to von Delft. Covid cases have surged again this holiday season, with the rise of a new variant called JN.1 reminding us that the virus is still changing to evade the immunity we've built up so far. Just before Christmas, UK authorities said about one in every 24 people in England and Scotland had the disease. An accessible antiviral could help people return to work more quickly, and it could also be tested as a potential treatment for long Covid. "We know from experience in viral disease that there will be resistance variants evolving over time," von Delft said. "We'll need more than one."

Andy Maxwell reports via TorrentFreak: As the crew of Artemis 2 prepare to become the first humans to fly to the moon since 1972, the possibilities of space travel are once again igniting imaginations globally. More than 92% of internet users who want to learn more about this historic mission and the program in general are statistically likely to use Google search. Behind the scenes, however, the ability to find relevant content is under attack. Blundering DMCA takedown notices sent by a company calling itself DMCA Piracy Prevention Inc. claim to protect the rights of an OnlyFans/Instagram model working under the name 'Artemis'. Instead, keyword-based systems that fail to discriminate between copyright-infringing content and that referencing the word Artemis in any other context, are flooding towards Google. They contain demands to completely deindex non-infringing, unrelated content, produced by innocent third parties all over the world.

A recent deindexing demand dated December 13, 2022, lists DMCA Piracy Prevention Inc. of Canada as the sender. The name of the content owner is redacted but the notice itself states that the company represents a content creator performing under the name Artemis. The notice demands the removal of 3,617 URLs from Google search. If successful, those URLs would be completely unfindable by more than 92% of the world's population who use that search engine. [...] At least 9 of the first 20 URLs in the notice demand the removal of non-infringing articles and news reports referencing the Artemis space program. None have anything to do with the content the sender claims to protect. [...]

Theories as to who might own and/or operate DMCA Piracy Prevention Inc. aren't hard to find but the company does exist and is registered as a corporate entity in Canada. Registered at the same address is a company with remarkably similar details. BranditScan is a corporate entity operating in exactly the same market offering similar if not identical services. BranditScan has sent DMCA takedown notices to Google under three different notifier accounts.

Following policy adjustments by the U.S. Citizenship and Immigration Services (USCIS) in January, more foreign-born workers in science, technology, engineering, and math (STEM) fields are able to live and work permanently in the United States. "The jump comes after USCIS in January 2022 tweaked its guidance criteria relating to two visa categories available to STEM workers," reports Science Magazine. "One is the O-1A, a temporary visa for 'aliens of extraordinary ability' that often paves the way to a green card. The second, which bestows a green card on those with advanced STEM degrees, governs a subset of an EB-2 (employment-based) visa." From the report: The USCIS data, reported exclusively by ScienceInsider, show that the number of O-1A visas awarded in the first year of the revised guidance jumped by almost 30%, to 4570, and held steady in fiscal year 2023, which ended on 30 September. Similarly, the number of STEM EB-2 visas approved in 2022 after a "national interest" waiver shot up by 55% over 2021, to 70,240, and stayed at that level this year. "I'm seeing more aspiring and early-stage startup founders believe there's a way forward for them," says Silicon Valley immigration attorney Sophie Alcorn. She predicts the policy changes will result in "new technology startups that would not have otherwise been created."

President Joe Biden has long sought to make it easier for foreign-born STEM workers to remain in the country and use their talent to spur the U.S. economy. But under the terms of a 1990 law, only 140,000 employment-based green cards may be issued annually, and no more than 7% of those can go to citizens of any one country. The ceiling is well below the demand. And the country quotas have created decades-long queues for scientists and high-tech entrepreneurs born in India and China. The 2022 guidance doesn't alter those limits on employment-based green cards but clarifies the visa process for foreign-born scientists pending any significant changes to the 1990 law. The O-1A work visa, which can be renewed indefinitely, was designed to accelerate the path to a green card for foreign-born high-tech entrepreneurs.

Although there is no cap on the number of O-1A visas awarded, foreign-born scientists have largely ignored this option because it wasn't clear what metrics USCIS would use to assess their application. The 2022 guidance on O-1As removed that uncertainty by listing eight criteria -- including awards, peer-reviewed publications, and reviewing the work of other scientistsâ"and stipulating that applicants need to satisfy at least three of them. The second visa policy change affects those with advanced STEM degrees seeking the national interest waiver for an EB-2. Under the normal process of obtaining such a visa, the Department of Labor requires employers to first satisfy rules meant to protect U.S. workers from foreign competition, for example, by showing that the company has failed to find a qualified domestic worker and that the job will pay the prevailing wage. That time-consuming exercise can be waived if visa applicants can prove they are doing "exceptional" work of "substantial merit and national importance." But once again, the standard for determining whether the labor-force requirements can be waived was vague, so relatively few STEM workers chose that route. The 2022 USCIS guidance not only specifies criteria, which closely track those for the nonimmigrant, O-1A visa, but also allows scientists to sponsor themselves.